nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—ABCB1—ovarian cancer	0.313	1	CbGaD
Azelastine—ABCB1—Topotecan—ovarian cancer	0.0497	0.118	CbGbCtD
Azelastine—CYP3A5—Paclitaxel—ovarian cancer	0.0378	0.0894	CbGbCtD
Azelastine—CYP2C8—Paclitaxel—ovarian cancer	0.0363	0.086	CbGbCtD
Azelastine—ABCB1—Vinorelbine—ovarian cancer	0.035	0.0829	CbGbCtD
Azelastine—CYP2D6—Vinorelbine—ovarian cancer	0.033	0.0781	CbGbCtD
Azelastine—CYP3A4—Topotecan—ovarian cancer	0.0298	0.0705	CbGbCtD
Azelastine—CYP3A5—Docetaxel—ovarian cancer	0.0273	0.0647	CbGbCtD
Azelastine—CYP2B6—Doxorubicin—ovarian cancer	0.0258	0.0612	CbGbCtD
Azelastine—CYP2C9—Paclitaxel—ovarian cancer	0.0253	0.06	CbGbCtD
Azelastine—ABCB1—Paclitaxel—ovarian cancer	0.0246	0.0582	CbGbCtD
Azelastine—CYP3A4—Vinorelbine—ovarian cancer	0.021	0.0496	CbGbCtD
Azelastine—ABCB1—Docetaxel—ovarian cancer	0.0178	0.0421	CbGbCtD
Azelastine—CYP3A4—Paclitaxel—ovarian cancer	0.0147	0.0349	CbGbCtD
Azelastine—ABCB1—Doxorubicin—ovarian cancer	0.0133	0.0314	CbGbCtD
Azelastine—CYP2D6—Doxorubicin—ovarian cancer	0.0125	0.0296	CbGbCtD
Azelastine—CYP3A4—Docetaxel—ovarian cancer	0.0107	0.0252	CbGbCtD
Azelastine—CYP3A4—Doxorubicin—ovarian cancer	0.00794	0.0188	CbGbCtD
Azelastine—KCNH2—myometrium—ovarian cancer	0.000677	0.0352	CbGeAlD
Azelastine—CYP2A6—vagina—ovarian cancer	0.000582	0.0303	CbGeAlD
Azelastine—HRH1—myometrium—ovarian cancer	0.000543	0.0282	CbGeAlD
Azelastine—KCNH2—uterine cervix—ovarian cancer	0.000527	0.0274	CbGeAlD
Azelastine—KCNH2—endometrium—ovarian cancer	0.000477	0.0248	CbGeAlD
Azelastine—CYP1A1—epithelium—ovarian cancer	0.000449	0.0233	CbGeAlD
Azelastine—CYP1A1—uterine cervix—ovarian cancer	0.000445	0.0232	CbGeAlD
Azelastine—KCNH2—uterus—ovarian cancer	0.000439	0.0228	CbGeAlD
Azelastine—CYP2C8—endometrium—ovarian cancer	0.000436	0.0227	CbGeAlD
Azelastine—CYP3A5—uterine cervix—ovarian cancer	0.000435	0.0226	CbGeAlD
Azelastine—HRH1—epithelium—ovarian cancer	0.000426	0.0222	CbGeAlD
Azelastine—HRH1—uterine cervix—ovarian cancer	0.000422	0.022	CbGeAlD
Azelastine—Eczema—Epirubicin—ovarian cancer	0.000403	0.00198	CcSEcCtD
Azelastine—Abnormal vision—Doxorubicin—ovarian cancer	0.000403	0.00197	CcSEcCtD
Azelastine—HRH1—decidua—ovarian cancer	0.000402	0.0209	CbGeAlD
Azelastine—Conjunctivitis—Docetaxel—ovarian cancer	0.000402	0.00197	CcSEcCtD
Azelastine—Eye pain—Epirubicin—ovarian cancer	0.000401	0.00197	CcSEcCtD
Azelastine—Mental disability—Doxorubicin—ovarian cancer	0.000401	0.00196	CcSEcCtD
Azelastine—Fatigue—Vinorelbine—ovarian cancer	0.000399	0.00196	CcSEcCtD
Azelastine—Hypersensitivity—Topotecan—ovarian cancer	0.000399	0.00196	CcSEcCtD
Azelastine—Constipation—Vinorelbine—ovarian cancer	0.000396	0.00194	CcSEcCtD
Azelastine—Pain—Vinorelbine—ovarian cancer	0.000396	0.00194	CcSEcCtD
Azelastine—KCNH2—female reproductive system—ovarian cancer	0.000395	0.0205	CbGeAlD
Azelastine—Hypersensitivity—Melphalan—ovarian cancer	0.000391	0.00191	CcSEcCtD
Azelastine—Epistaxis—Docetaxel—ovarian cancer	0.000391	0.00191	CcSEcCtD
Azelastine—Asthenia—Topotecan—ovarian cancer	0.000388	0.0019	CcSEcCtD
Azelastine—Vomiting—Chlorambucil—ovarian cancer	0.000387	0.0019	CcSEcCtD
Azelastine—Increased appetite—Epirubicin—ovarian cancer	0.000386	0.00189	CcSEcCtD
Azelastine—Pruritus—Topotecan—ovarian cancer	0.000383	0.00188	CcSEcCtD
Azelastine—HRH1—endometrium—ovarian cancer	0.000382	0.0199	CbGeAlD
Azelastine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000382	0.00187	CcSEcCtD
Azelastine—Asthenia—Melphalan—ovarian cancer	0.00038	0.00186	CcSEcCtD
Azelastine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000379	0.00186	CcSEcCtD
Azelastine—Pruritus—Melphalan—ovarian cancer	0.000375	0.00184	CcSEcCtD
Azelastine—Tension—Paclitaxel—ovarian cancer	0.000375	0.00184	CcSEcCtD
Azelastine—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000374	0.00184	CcSEcCtD
Azelastine—CYP2C19—vagina—ovarian cancer	0.000374	0.0195	CbGeAlD
Azelastine—Dysgeusia—Paclitaxel—ovarian cancer	0.000374	0.00183	CcSEcCtD
Azelastine—Eczema—Doxorubicin—ovarian cancer	0.000373	0.00183	CcSEcCtD
Azelastine—KCNH2—bone marrow—ovarian cancer	0.000373	0.0194	CbGeAlD
Azelastine—Rhinitis—Docetaxel—ovarian cancer	0.000373	0.00183	CcSEcCtD
Azelastine—Eye pain—Doxorubicin—ovarian cancer	0.000371	0.00182	CcSEcCtD
Azelastine—CYP1A1—uterus—ovarian cancer	0.000371	0.0193	CbGeAlD
Azelastine—Nervousness—Paclitaxel—ovarian cancer	0.000371	0.00182	CcSEcCtD
Azelastine—Diarrhoea—Topotecan—ovarian cancer	0.00037	0.00182	CcSEcCtD
Azelastine—Hypoaesthesia—Docetaxel—ovarian cancer	0.00037	0.00181	CcSEcCtD
Azelastine—Back pain—Paclitaxel—ovarian cancer	0.000369	0.00181	CcSEcCtD
Azelastine—Pharyngitis—Docetaxel—ovarian cancer	0.000369	0.00181	CcSEcCtD
Azelastine—Body temperature increased—Vinorelbine—ovarian cancer	0.000366	0.00179	CcSEcCtD
Azelastine—Abdominal pain—Vinorelbine—ovarian cancer	0.000366	0.00179	CcSEcCtD
Azelastine—CYP2B6—gonad—ovarian cancer	0.000363	0.0189	CbGeAlD
Azelastine—Diarrhoea—Melphalan—ovarian cancer	0.000363	0.00178	CcSEcCtD
Azelastine—CYP2C8—female reproductive system—ovarian cancer	0.000361	0.0188	CbGeAlD
Azelastine—Nausea—Chlorambucil—ovarian cancer	0.000361	0.00177	CcSEcCtD
Azelastine—Vision blurred—Paclitaxel—ovarian cancer	0.00036	0.00176	CcSEcCtD
Azelastine—KCNH2—female gonad—ovarian cancer	0.000359	0.0187	CbGeAlD
Azelastine—Visual impairment—Docetaxel—ovarian cancer	0.000358	0.00176	CcSEcCtD
Azelastine—Dizziness—Topotecan—ovarian cancer	0.000358	0.00176	CcSEcCtD
Azelastine—KCNH2—vagina—ovarian cancer	0.000357	0.0186	CbGeAlD
Azelastine—Increased appetite—Doxorubicin—ovarian cancer	0.000357	0.00175	CcSEcCtD
Azelastine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000354	0.00174	CcSEcCtD
Azelastine—Agitation—Paclitaxel—ovarian cancer	0.000351	0.00172	CcSEcCtD
Azelastine—Face oedema—Epirubicin—ovarian cancer	0.00035	0.00171	CcSEcCtD
Azelastine—Eye disorder—Docetaxel—ovarian cancer	0.000347	0.0017	CcSEcCtD
Azelastine—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.000346	0.0017	CcSEcCtD
Azelastine—Flushing—Docetaxel—ovarian cancer	0.000345	0.00169	CcSEcCtD
Azelastine—Vomiting—Topotecan—ovarian cancer	0.000344	0.00169	CcSEcCtD
Azelastine—Malaise—Paclitaxel—ovarian cancer	0.000344	0.00169	CcSEcCtD
Azelastine—Vertigo—Paclitaxel—ovarian cancer	0.000343	0.00168	CcSEcCtD
Azelastine—Rash—Topotecan—ovarian cancer	0.000341	0.00167	CcSEcCtD
Azelastine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000341	0.00167	CcSEcCtD
Azelastine—Dermatitis—Topotecan—ovarian cancer	0.000341	0.00167	CcSEcCtD
Azelastine—Headache—Topotecan—ovarian cancer	0.000339	0.00166	CcSEcCtD
Azelastine—Palpitations—Paclitaxel—ovarian cancer	0.000337	0.00165	CcSEcCtD
Azelastine—Vomiting—Melphalan—ovarian cancer	0.000337	0.00165	CcSEcCtD
Azelastine—Rash—Melphalan—ovarian cancer	0.000334	0.00164	CcSEcCtD
Azelastine—Dermatitis—Melphalan—ovarian cancer	0.000334	0.00164	CcSEcCtD
Azelastine—CYP1A1—female reproductive system—ovarian cancer	0.000333	0.0173	CbGeAlD
Azelastine—Cough—Paclitaxel—ovarian cancer	0.000333	0.00163	CcSEcCtD
Azelastine—Asthenia—Vinorelbine—ovarian cancer	0.000332	0.00163	CcSEcCtD
Azelastine—Hypertension—Paclitaxel—ovarian cancer	0.00033	0.00162	CcSEcCtD
Azelastine—Pruritus—Vinorelbine—ovarian cancer	0.000328	0.00161	CcSEcCtD
Azelastine—CYP2C8—vagina—ovarian cancer	0.000327	0.017	CbGeAlD
Azelastine—Chest pain—Paclitaxel—ovarian cancer	0.000325	0.00159	CcSEcCtD
Azelastine—Myalgia—Paclitaxel—ovarian cancer	0.000325	0.00159	CcSEcCtD
Azelastine—CYP2B6—female reproductive system—ovarian cancer	0.000324	0.0169	CbGeAlD
Azelastine—Nasopharyngitis—Epirubicin—ovarian cancer	0.000324	0.00159	CcSEcCtD
Azelastine—Anxiety—Paclitaxel—ovarian cancer	0.000324	0.00159	CcSEcCtD
Azelastine—Face oedema—Doxorubicin—ovarian cancer	0.000324	0.00159	CcSEcCtD
Azelastine—Nausea—Topotecan—ovarian cancer	0.000322	0.00158	CcSEcCtD
Azelastine—Discomfort—Paclitaxel—ovarian cancer	0.000321	0.00157	CcSEcCtD
Azelastine—CYP2C9—female reproductive system—ovarian cancer	0.000321	0.0167	CbGeAlD
Azelastine—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00032	0.00157	CcSEcCtD
Azelastine—KCNH2—testis—ovarian cancer	0.000319	0.0166	CbGeAlD
Azelastine—Dry mouth—Paclitaxel—ovarian cancer	0.000318	0.00156	CcSEcCtD
Azelastine—Diarrhoea—Vinorelbine—ovarian cancer	0.000317	0.00155	CcSEcCtD
Azelastine—Dysgeusia—Docetaxel—ovarian cancer	0.000317	0.00155	CcSEcCtD
Azelastine—HRH1—female reproductive system—ovarian cancer	0.000317	0.0165	CbGeAlD
Azelastine—Nausea—Melphalan—ovarian cancer	0.000315	0.00154	CcSEcCtD
Azelastine—Confusional state—Paclitaxel—ovarian cancer	0.000314	0.00154	CcSEcCtD
Azelastine—Asthma—Epirubicin—ovarian cancer	0.000313	0.00154	CcSEcCtD
Azelastine—Back pain—Docetaxel—ovarian cancer	0.000313	0.00153	CcSEcCtD
Azelastine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000312	0.00153	CcSEcCtD
Azelastine—Infection—Paclitaxel—ovarian cancer	0.00031	0.00152	CcSEcCtD
Azelastine—Dizziness—Vinorelbine—ovarian cancer	0.000306	0.0015	CcSEcCtD
Azelastine—CYP2E1—female reproductive system—ovarian cancer	0.000304	0.0158	CbGeAlD
Azelastine—Tachycardia—Paclitaxel—ovarian cancer	0.000304	0.00149	CcSEcCtD
Azelastine—CYP1A1—female gonad—ovarian cancer	0.000303	0.0158	CbGeAlD
Azelastine—CYP1A1—vagina—ovarian cancer	0.000302	0.0157	CbGeAlD
Azelastine—Bronchitis—Epirubicin—ovarian cancer	0.000301	0.00148	CcSEcCtD
Azelastine—Nasopharyngitis—Doxorubicin—ovarian cancer	0.0003	0.00147	CcSEcCtD
Azelastine—ABCB1—myometrium—ovarian cancer	0.000297	0.0155	CbGeAlD
Azelastine—CYP3A5—female gonad—ovarian cancer	0.000297	0.0154	CbGeAlD
Azelastine—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000296	0.00145	CcSEcCtD
Azelastine—CYP3A5—vagina—ovarian cancer	0.000295	0.0153	CbGeAlD
Azelastine—Vomiting—Vinorelbine—ovarian cancer	0.000295	0.00144	CcSEcCtD
Azelastine—CYP2B6—vagina—ovarian cancer	0.000293	0.0152	CbGeAlD
Azelastine—Rash—Vinorelbine—ovarian cancer	0.000292	0.00143	CcSEcCtD
Azelastine—Dermatitis—Vinorelbine—ovarian cancer	0.000292	0.00143	CcSEcCtD
Azelastine—CYP2C8—testis—ovarian cancer	0.000292	0.0152	CbGeAlD
Azelastine—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000291	0.00143	CcSEcCtD
Azelastine—Headache—Vinorelbine—ovarian cancer	0.00029	0.00142	CcSEcCtD
Azelastine—Asthma—Doxorubicin—ovarian cancer	0.00029	0.00142	CcSEcCtD
Azelastine—Pollakiuria—Epirubicin—ovarian cancer	0.000289	0.00142	CcSEcCtD
Azelastine—HRH1—female gonad—ovarian cancer	0.000288	0.015	CbGeAlD
Azelastine—HRH1—vagina—ovarian cancer	0.000286	0.0149	CbGeAlD
Azelastine—Palpitations—Docetaxel—ovarian cancer	0.000286	0.0014	CcSEcCtD
Azelastine—ABCB1—embryo—ovarian cancer	0.000286	0.0149	CbGeAlD
Azelastine—Weight increased—Epirubicin—ovarian cancer	0.000285	0.0014	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000284	0.00139	CcSEcCtD
Azelastine—Cough—Docetaxel—ovarian cancer	0.000282	0.00138	CcSEcCtD
Azelastine—Paraesthesia—Paclitaxel—ovarian cancer	0.00028	0.00137	CcSEcCtD
Azelastine—Hypertension—Docetaxel—ovarian cancer	0.000279	0.00137	CcSEcCtD
Azelastine—Bronchitis—Doxorubicin—ovarian cancer	0.000279	0.00137	CcSEcCtD
Azelastine—Dyspnoea—Paclitaxel—ovarian cancer	0.000278	0.00136	CcSEcCtD
Azelastine—Somnolence—Paclitaxel—ovarian cancer	0.000277	0.00136	CcSEcCtD
Azelastine—Myalgia—Docetaxel—ovarian cancer	0.000275	0.00135	CcSEcCtD
Azelastine—Chest pain—Docetaxel—ovarian cancer	0.000275	0.00135	CcSEcCtD
Azelastine—Nausea—Vinorelbine—ovarian cancer	0.000275	0.00135	CcSEcCtD
Azelastine—Conjunctivitis—Epirubicin—ovarian cancer	0.000271	0.00133	CcSEcCtD
Azelastine—Dry mouth—Docetaxel—ovarian cancer	0.000269	0.00132	CcSEcCtD
Azelastine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000269	0.00132	CcSEcCtD
Azelastine—Fatigue—Paclitaxel—ovarian cancer	0.000269	0.00132	CcSEcCtD
Azelastine—Pollakiuria—Doxorubicin—ovarian cancer	0.000268	0.00131	CcSEcCtD
Azelastine—Constipation—Paclitaxel—ovarian cancer	0.000266	0.00131	CcSEcCtD
Azelastine—Pain—Paclitaxel—ovarian cancer	0.000266	0.00131	CcSEcCtD
Azelastine—Haematuria—Epirubicin—ovarian cancer	0.000266	0.00131	CcSEcCtD
Azelastine—Confusional state—Docetaxel—ovarian cancer	0.000266	0.00131	CcSEcCtD
Azelastine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000264	0.00129	CcSEcCtD
Azelastine—Weight increased—Doxorubicin—ovarian cancer	0.000264	0.00129	CcSEcCtD
Azelastine—Epistaxis—Epirubicin—ovarian cancer	0.000263	0.00129	CcSEcCtD
Azelastine—Infection—Docetaxel—ovarian cancer	0.000262	0.00129	CcSEcCtD
Azelastine—Sinusitis—Epirubicin—ovarian cancer	0.000262	0.00128	CcSEcCtD
Azelastine—CYP2B6—testis—ovarian cancer	0.000262	0.0136	CbGeAlD
Azelastine—Tachycardia—Docetaxel—ovarian cancer	0.000258	0.00126	CcSEcCtD
Azelastine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000257	0.00126	CcSEcCtD
Azelastine—HRH1—testis—ovarian cancer	0.000255	0.0133	CbGeAlD
Azelastine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000255	0.00125	CcSEcCtD
Azelastine—Rhinitis—Epirubicin—ovarian cancer	0.000251	0.00123	CcSEcCtD
Azelastine—Conjunctivitis—Doxorubicin—ovarian cancer	0.000251	0.00123	CcSEcCtD
Azelastine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000249	0.00122	CcSEcCtD
Azelastine—Pharyngitis—Epirubicin—ovarian cancer	0.000249	0.00122	CcSEcCtD
Azelastine—Haematuria—Doxorubicin—ovarian cancer	0.000246	0.00121	CcSEcCtD
Azelastine—Abdominal pain—Paclitaxel—ovarian cancer	0.000246	0.00121	CcSEcCtD
Azelastine—Body temperature increased—Paclitaxel—ovarian cancer	0.000246	0.00121	CcSEcCtD
Azelastine—CYP2E1—testis—ovarian cancer	0.000245	0.0128	CbGeAlD
Azelastine—CYP3A4—female reproductive system—ovarian cancer	0.000245	0.0127	CbGeAlD
Azelastine—Epistaxis—Doxorubicin—ovarian cancer	0.000244	0.00119	CcSEcCtD
Azelastine—Sinusitis—Doxorubicin—ovarian cancer	0.000242	0.00119	CcSEcCtD
Azelastine—Visual impairment—Epirubicin—ovarian cancer	0.000242	0.00118	CcSEcCtD
Azelastine—CYP2D6—female reproductive system—ovarian cancer	0.000241	0.0125	CbGeAlD
Azelastine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000241	0.00118	CcSEcCtD
Azelastine—Paraesthesia—Docetaxel—ovarian cancer	0.000237	0.00116	CcSEcCtD
Azelastine—Dyspnoea—Docetaxel—ovarian cancer	0.000235	0.00115	CcSEcCtD
Azelastine—Somnolence—Docetaxel—ovarian cancer	0.000235	0.00115	CcSEcCtD
Azelastine—Eye disorder—Epirubicin—ovarian cancer	0.000234	0.00115	CcSEcCtD
Azelastine—ABCB1—epithelium—ovarian cancer	0.000233	0.0121	CbGeAlD
Azelastine—Flushing—Epirubicin—ovarian cancer	0.000233	0.00114	CcSEcCtD
Azelastine—Rhinitis—Doxorubicin—ovarian cancer	0.000233	0.00114	CcSEcCtD
Azelastine—ABCB1—uterine cervix—ovarian cancer	0.000231	0.012	CbGeAlD
Azelastine—KCNH2—lymph node—ovarian cancer	0.000231	0.012	CbGeAlD
Azelastine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000231	0.00113	CcSEcCtD
Azelastine—Pharyngitis—Doxorubicin—ovarian cancer	0.00023	0.00113	CcSEcCtD
Azelastine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00023	0.00113	CcSEcCtD
Azelastine—Fatigue—Docetaxel—ovarian cancer	0.000228	0.00112	CcSEcCtD
Azelastine—Constipation—Docetaxel—ovarian cancer	0.000226	0.00111	CcSEcCtD
Azelastine—Pain—Docetaxel—ovarian cancer	0.000226	0.00111	CcSEcCtD
Azelastine—Visual impairment—Doxorubicin—ovarian cancer	0.000224	0.0011	CcSEcCtD
Azelastine—Asthenia—Paclitaxel—ovarian cancer	0.000224	0.0011	CcSEcCtD
Azelastine—Pruritus—Paclitaxel—ovarian cancer	0.00022	0.00108	CcSEcCtD
Azelastine—ABCB1—decidua—ovarian cancer	0.00022	0.0115	CbGeAlD
Azelastine—CYP2D6—female gonad—ovarian cancer	0.000219	0.0114	CbGeAlD
Azelastine—Feeling abnormal—Docetaxel—ovarian cancer	0.000218	0.00107	CcSEcCtD
Azelastine—Eye disorder—Doxorubicin—ovarian cancer	0.000217	0.00106	CcSEcCtD
Azelastine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000216	0.00106	CcSEcCtD
Azelastine—Flushing—Doxorubicin—ovarian cancer	0.000215	0.00106	CcSEcCtD
Azelastine—Tension—Epirubicin—ovarian cancer	0.000214	0.00105	CcSEcCtD
Azelastine—Dysgeusia—Epirubicin—ovarian cancer	0.000214	0.00105	CcSEcCtD
Azelastine—Diarrhoea—Paclitaxel—ovarian cancer	0.000213	0.00104	CcSEcCtD
Azelastine—Nervousness—Epirubicin—ovarian cancer	0.000212	0.00104	CcSEcCtD
Azelastine—Back pain—Epirubicin—ovarian cancer	0.000211	0.00103	CcSEcCtD
Azelastine—ABCB1—endometrium—ovarian cancer	0.000209	0.0109	CbGeAlD
Azelastine—Body temperature increased—Docetaxel—ovarian cancer	0.000209	0.00102	CcSEcCtD
Azelastine—Abdominal pain—Docetaxel—ovarian cancer	0.000209	0.00102	CcSEcCtD
Azelastine—Dizziness—Paclitaxel—ovarian cancer	0.000206	0.00101	CcSEcCtD
Azelastine—Vision blurred—Epirubicin—ovarian cancer	0.000206	0.00101	CcSEcCtD
Azelastine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000202	0.000993	CcSEcCtD
Azelastine—Agitation—Epirubicin—ovarian cancer	0.000201	0.000983	CcSEcCtD
Azelastine—Tension—Doxorubicin—ovarian cancer	0.000198	0.000971	CcSEcCtD
Azelastine—Vomiting—Paclitaxel—ovarian cancer	0.000198	0.000971	CcSEcCtD
Azelastine—Dysgeusia—Doxorubicin—ovarian cancer	0.000198	0.000969	CcSEcCtD
Azelastine—Malaise—Epirubicin—ovarian cancer	0.000197	0.000965	CcSEcCtD
Azelastine—Rash—Paclitaxel—ovarian cancer	0.000196	0.000963	CcSEcCtD
Azelastine—Dermatitis—Paclitaxel—ovarian cancer	0.000196	0.000962	CcSEcCtD
Azelastine—Nervousness—Doxorubicin—ovarian cancer	0.000196	0.000961	CcSEcCtD
Azelastine—Vertigo—Epirubicin—ovarian cancer	0.000196	0.000961	CcSEcCtD
Azelastine—Back pain—Doxorubicin—ovarian cancer	0.000195	0.000957	CcSEcCtD
Azelastine—Headache—Paclitaxel—ovarian cancer	0.000195	0.000957	CcSEcCtD
Azelastine—CYP1A1—lymph node—ovarian cancer	0.000195	0.0101	CbGeAlD
Azelastine—Hypersensitivity—Docetaxel—ovarian cancer	0.000195	0.000954	CcSEcCtD
Azelastine—CYP2D6—testis—ovarian cancer	0.000194	0.0101	CbGeAlD
Azelastine—ABCB1—gonad—ovarian cancer	0.000194	0.0101	CbGeAlD
Azelastine—Palpitations—Epirubicin—ovarian cancer	0.000193	0.000945	CcSEcCtD
Azelastine—ABCB1—uterus—ovarian cancer	0.000193	0.01	CbGeAlD
Azelastine—Cough—Epirubicin—ovarian cancer	0.00019	0.000934	CcSEcCtD
Azelastine—Vision blurred—Doxorubicin—ovarian cancer	0.00019	0.000933	CcSEcCtD
Azelastine—Asthenia—Docetaxel—ovarian cancer	0.000189	0.000929	CcSEcCtD
Azelastine—Hypertension—Epirubicin—ovarian cancer	0.000188	0.000924	CcSEcCtD
Azelastine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000187	0.000918	CcSEcCtD
Azelastine—Pruritus—Docetaxel—ovarian cancer	0.000187	0.000916	CcSEcCtD
Azelastine—Chest pain—Epirubicin—ovarian cancer	0.000186	0.000911	CcSEcCtD
Azelastine—Myalgia—Epirubicin—ovarian cancer	0.000186	0.000911	CcSEcCtD
Azelastine—Agitation—Doxorubicin—ovarian cancer	0.000186	0.00091	CcSEcCtD
Azelastine—Anxiety—Epirubicin—ovarian cancer	0.000185	0.000908	CcSEcCtD
Azelastine—HRH1—lymph node—ovarian cancer	0.000185	0.00963	CbGeAlD
Azelastine—Nausea—Paclitaxel—ovarian cancer	0.000185	0.000907	CcSEcCtD
Azelastine—Discomfort—Epirubicin—ovarian cancer	0.000184	0.0009	CcSEcCtD
Azelastine—Malaise—Doxorubicin—ovarian cancer	0.000182	0.000893	CcSEcCtD
Azelastine—Dry mouth—Epirubicin—ovarian cancer	0.000182	0.000891	CcSEcCtD
Azelastine—Vertigo—Doxorubicin—ovarian cancer	0.000181	0.000889	CcSEcCtD
Azelastine—Diarrhoea—Docetaxel—ovarian cancer	0.000181	0.000886	CcSEcCtD
Azelastine—Confusional state—Epirubicin—ovarian cancer	0.00018	0.00088	CcSEcCtD
Azelastine—Palpitations—Doxorubicin—ovarian cancer	0.000178	0.000875	CcSEcCtD
Azelastine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000178	0.000873	CcSEcCtD
Azelastine—Infection—Epirubicin—ovarian cancer	0.000177	0.000867	CcSEcCtD
Azelastine—Cough—Doxorubicin—ovarian cancer	0.000176	0.000864	CcSEcCtD
Azelastine—Dizziness—Docetaxel—ovarian cancer	0.000175	0.000856	CcSEcCtD
Azelastine—Hypertension—Doxorubicin—ovarian cancer	0.000174	0.000855	CcSEcCtD
Azelastine—Tachycardia—Epirubicin—ovarian cancer	0.000174	0.000852	CcSEcCtD
Azelastine—ABCB1—female reproductive system—ovarian cancer	0.000173	0.00901	CbGeAlD
Azelastine—Myalgia—Doxorubicin—ovarian cancer	0.000172	0.000843	CcSEcCtD
Azelastine—Chest pain—Doxorubicin—ovarian cancer	0.000172	0.000843	CcSEcCtD
Azelastine—Anxiety—Doxorubicin—ovarian cancer	0.000171	0.00084	CcSEcCtD
Azelastine—Discomfort—Doxorubicin—ovarian cancer	0.00017	0.000833	CcSEcCtD
Azelastine—Dry mouth—Doxorubicin—ovarian cancer	0.000168	0.000824	CcSEcCtD
Azelastine—Vomiting—Docetaxel—ovarian cancer	0.000168	0.000823	CcSEcCtD
Azelastine—Rash—Docetaxel—ovarian cancer	0.000167	0.000816	CcSEcCtD
Azelastine—Dermatitis—Docetaxel—ovarian cancer	0.000166	0.000815	CcSEcCtD
Azelastine—Confusional state—Doxorubicin—ovarian cancer	0.000166	0.000815	CcSEcCtD
Azelastine—Headache—Docetaxel—ovarian cancer	0.000165	0.000811	CcSEcCtD
Azelastine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000165	0.000808	CcSEcCtD
Azelastine—Infection—Doxorubicin—ovarian cancer	0.000164	0.000803	CcSEcCtD
Azelastine—ABCB1—bone marrow—ovarian cancer	0.000164	0.00851	CbGeAlD
Azelastine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000162	0.000795	CcSEcCtD
Azelastine—Tachycardia—Doxorubicin—ovarian cancer	0.000161	0.000788	CcSEcCtD
Azelastine—Paraesthesia—Epirubicin—ovarian cancer	0.00016	0.000784	CcSEcCtD
Azelastine—Dyspnoea—Epirubicin—ovarian cancer	0.000159	0.000778	CcSEcCtD
Azelastine—Somnolence—Epirubicin—ovarian cancer	0.000158	0.000776	CcSEcCtD
Azelastine—ABCB1—female gonad—ovarian cancer	0.000158	0.0082	CbGeAlD
Azelastine—Nausea—Docetaxel—ovarian cancer	0.000157	0.000769	CcSEcCtD
Azelastine—ABCB1—vagina—ovarian cancer	0.000157	0.00815	CbGeAlD
Azelastine—Fatigue—Epirubicin—ovarian cancer	0.000154	0.000753	CcSEcCtD
Azelastine—Pain—Epirubicin—ovarian cancer	0.000152	0.000747	CcSEcCtD
Azelastine—Constipation—Epirubicin—ovarian cancer	0.000152	0.000747	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00015	0.000736	CcSEcCtD
Azelastine—Paraesthesia—Doxorubicin—ovarian cancer	0.000148	0.000725	CcSEcCtD
Azelastine—Dyspnoea—Doxorubicin—ovarian cancer	0.000147	0.00072	CcSEcCtD
Azelastine—Feeling abnormal—Epirubicin—ovarian cancer	0.000147	0.000719	CcSEcCtD
Azelastine—Somnolence—Doxorubicin—ovarian cancer	0.000147	0.000718	CcSEcCtD
Azelastine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000146	0.000714	CcSEcCtD
Azelastine—Fatigue—Doxorubicin—ovarian cancer	0.000142	0.000696	CcSEcCtD
Azelastine—Pain—Doxorubicin—ovarian cancer	0.000141	0.000691	CcSEcCtD
Azelastine—Constipation—Doxorubicin—ovarian cancer	0.000141	0.000691	CcSEcCtD
Azelastine—Abdominal pain—Epirubicin—ovarian cancer	0.000141	0.00069	CcSEcCtD
Azelastine—Body temperature increased—Epirubicin—ovarian cancer	0.000141	0.00069	CcSEcCtD
Azelastine—ABCB1—testis—ovarian cancer	0.00014	0.00727	CbGeAlD
Azelastine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000136	0.000666	CcSEcCtD
Azelastine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000135	0.000661	CcSEcCtD
Azelastine—Hypersensitivity—Epirubicin—ovarian cancer	0.000131	0.000643	CcSEcCtD
Azelastine—Body temperature increased—Doxorubicin—ovarian cancer	0.00013	0.000639	CcSEcCtD
Azelastine—Abdominal pain—Doxorubicin—ovarian cancer	0.00013	0.000639	CcSEcCtD
Azelastine—Asthenia—Epirubicin—ovarian cancer	0.000128	0.000626	CcSEcCtD
Azelastine—Pruritus—Epirubicin—ovarian cancer	0.000126	0.000618	CcSEcCtD
Azelastine—Diarrhoea—Epirubicin—ovarian cancer	0.000122	0.000597	CcSEcCtD
Azelastine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000121	0.000595	CcSEcCtD
Azelastine—Asthenia—Doxorubicin—ovarian cancer	0.000118	0.00058	CcSEcCtD
Azelastine—Dizziness—Epirubicin—ovarian cancer	0.000118	0.000577	CcSEcCtD
Azelastine—Pruritus—Doxorubicin—ovarian cancer	0.000117	0.000572	CcSEcCtD
Azelastine—Vomiting—Epirubicin—ovarian cancer	0.000113	0.000555	CcSEcCtD
Azelastine—Diarrhoea—Doxorubicin—ovarian cancer	0.000113	0.000553	CcSEcCtD
Azelastine—Rash—Epirubicin—ovarian cancer	0.000112	0.000551	CcSEcCtD
Azelastine—Dermatitis—Epirubicin—ovarian cancer	0.000112	0.00055	CcSEcCtD
Azelastine—Headache—Epirubicin—ovarian cancer	0.000112	0.000547	CcSEcCtD
Azelastine—Dizziness—Doxorubicin—ovarian cancer	0.000109	0.000534	CcSEcCtD
Azelastine—Nausea—Epirubicin—ovarian cancer	0.000106	0.000519	CcSEcCtD
Azelastine—Vomiting—Doxorubicin—ovarian cancer	0.000105	0.000514	CcSEcCtD
Azelastine—Rash—Doxorubicin—ovarian cancer	0.000104	0.000509	CcSEcCtD
Azelastine—Dermatitis—Doxorubicin—ovarian cancer	0.000104	0.000509	CcSEcCtD
Azelastine—Headache—Doxorubicin—ovarian cancer	0.000103	0.000506	CcSEcCtD
Azelastine—ABCB1—lymph node—ovarian cancer	0.000101	0.00527	CbGeAlD
Azelastine—Nausea—Doxorubicin—ovarian cancer	9.79e-05	0.00048	CcSEcCtD
Azelastine—CYP2B6—Metabolism—ABCB1—ovarian cancer	9.23e-06	0.000225	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—PIK3CA—ovarian cancer	9.2e-06	0.000224	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	9.18e-06	0.000223	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—SLC5A5—ovarian cancer	9.14e-06	0.000223	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.13e-06	0.000222	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—FASN—ovarian cancer	9.07e-06	0.000221	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—TYMS—ovarian cancer	9.06e-06	0.000221	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—CAV1—ovarian cancer	9.05e-06	0.00022	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.05e-06	0.00022	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—ABCB1—ovarian cancer	9.04e-06	0.00022	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—ABCB1—ovarian cancer	9.02e-06	0.00022	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CXCL8—ovarian cancer	8.96e-06	0.000218	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—CXCL8—ovarian cancer	8.93e-06	0.000217	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—SLC5A5—ovarian cancer	8.93e-06	0.000217	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TP53—ovarian cancer	8.9e-06	0.000217	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—YAP1—ovarian cancer	8.89e-06	0.000216	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—TYMS—ovarian cancer	8.88e-06	0.000216	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—TYMS—ovarian cancer	8.86e-06	0.000216	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—SLC2A1—ovarian cancer	8.83e-06	0.000215	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.79e-06	0.000214	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.65e-06	0.00021	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—SLC2A1—ovarian cancer	8.62e-06	0.00021	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL2—ovarian cancer	8.56e-06	0.000208	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—FASN—ovarian cancer	8.55e-06	0.000208	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—IL2—ovarian cancer	8.54e-06	0.000208	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TERT—ovarian cancer	8.53e-06	0.000208	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—ABCB1—ovarian cancer	8.52e-06	0.000207	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—HRAS—ovarian cancer	8.51e-06	0.000207	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—FASN—ovarian cancer	8.48e-06	0.000206	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CYP1B1—ovarian cancer	8.47e-06	0.000206	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CB—ovarian cancer	8.44e-06	0.000205	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	8.41e-06	0.000205	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	8.41e-06	0.000205	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.37e-06	0.000204	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—TYMS—ovarian cancer	8.37e-06	0.000204	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—SLC5A5—ovarian cancer	8.34e-06	0.000203	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CYP1B1—ovarian cancer	8.26e-06	0.000201	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CG—ovarian cancer	8.24e-06	0.000201	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—IL6—ovarian cancer	8.15e-06	0.000198	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	8.12e-06	0.000198	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CXCL8—ovarian cancer	8.11e-06	0.000197	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—SLC2A1—ovarian cancer	8.05e-06	0.000196	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CAV1—ovarian cancer	7.89e-06	0.000192	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.89e-06	0.000192	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ABCB1—ovarian cancer	7.81e-06	0.00019	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	7.79e-06	0.00019	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL2—ovarian cancer	7.75e-06	0.000189	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.73e-06	0.000188	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TERT—ovarian cancer	7.72e-06	0.000188	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP1B1—ovarian cancer	7.72e-06	0.000188	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—TYMS—ovarian cancer	7.67e-06	0.000187	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ESR1—ovarian cancer	7.6e-06	0.000185	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—AKT1—ovarian cancer	7.52e-06	0.000183	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	7.51e-06	0.000183	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL6ST—ovarian cancer	7.48e-06	0.000182	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.47e-06	0.000182	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPP2R1A—ovarian cancer	7.33e-06	0.000178	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CAV1—ovarian cancer	7.3e-06	0.000178	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CD—ovarian cancer	7.25e-06	0.000176	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—FASN—ovarian cancer	7.24e-06	0.000176	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—APC—ovarian cancer	7.19e-06	0.000175	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CG—ovarian cancer	7.19e-06	0.000175	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—NRAS—ovarian cancer	7.19e-06	0.000175	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CAV1—ovarian cancer	7.15e-06	0.000174	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CAV1—ovarian cancer	7.14e-06	0.000174	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CAV1—ovarian cancer	7.14e-06	0.000174	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	7.13e-06	0.000173	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ABCB1—ovarian cancer	6.97e-06	0.00017	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	6.91e-06	0.000168	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—MAPK3—ovarian cancer	6.88e-06	0.000168	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ESR1—ovarian cancer	6.88e-06	0.000168	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	6.88e-06	0.000167	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—YAP1—ovarian cancer	6.86e-06	0.000167	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—TYMS—ovarian cancer	6.85e-06	0.000167	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	6.85e-06	0.000167	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.81e-06	0.000166	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL6ST—ovarian cancer	6.77e-06	0.000165	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CAV1—ovarian cancer	6.74e-06	0.000164	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.74e-06	0.000164	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—TYMS—ovarian cancer	6.68e-06	0.000163	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CG—ovarian cancer	6.65e-06	0.000162	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	6.6e-06	0.000161	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—MAPK1—ovarian cancer	6.55e-06	0.000159	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—EGFR—ovarian cancer	6.55e-06	0.000159	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CG—ovarian cancer	6.51e-06	0.000159	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CG—ovarian cancer	6.51e-06	0.000158	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—APC—ovarian cancer	6.51e-06	0.000158	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—NRAS—ovarian cancer	6.51e-06	0.000158	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CG—ovarian cancer	6.5e-06	0.000158	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.44e-06	0.000157	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ABCB1—ovarian cancer	6.41e-06	0.000156	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ABCB1—ovarian cancer	6.36e-06	0.000155	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CD—ovarian cancer	6.32e-06	0.000154	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CB—ovarian cancer	6.32e-06	0.000154	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—TYMS—ovarian cancer	6.3e-06	0.000153	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—PIK3CA—ovarian cancer	6.26e-06	0.000152	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—TYMS—ovarian cancer	6.24e-06	0.000152	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—MAPK3—ovarian cancer	6.23e-06	0.000152	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—KRAS—ovarian cancer	6.19e-06	0.000151	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CAV1—ovarian cancer	6.18e-06	0.00015	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CG—ovarian cancer	6.14e-06	0.00015	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—MAPK1—ovarian cancer	5.93e-06	0.000144	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—EGFR—ovarian cancer	5.93e-06	0.000144	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.91e-06	0.000144	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	5.85e-06	0.000142	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CD—ovarian cancer	5.85e-06	0.000142	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.82e-06	0.000142	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CD—ovarian cancer	5.73e-06	0.000139	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CD—ovarian cancer	5.72e-06	0.000139	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CD—ovarian cancer	5.72e-06	0.000139	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PIK3CA—ovarian cancer	5.68e-06	0.000138	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—PIK3CA—ovarian cancer	5.67e-06	0.000138	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CG—ovarian cancer	5.63e-06	0.000137	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—KRAS—ovarian cancer	5.6e-06	0.000136	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—FASN—ovarian cancer	5.59e-06	0.000136	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	5.58e-06	0.000136	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CAV1—ovarian cancer	5.52e-06	0.000134	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	5.51e-06	0.000134	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	5.51e-06	0.000134	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.5e-06	0.000134	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTEN—ovarian cancer	5.46e-06	0.000133	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ABCB1—ovarian cancer	5.43e-06	0.000132	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CD—ovarian cancer	5.4e-06	0.000131	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CAV1—ovarian cancer	5.39e-06	0.000131	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—TYMS—ovarian cancer	5.34e-06	0.00013	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.31e-06	0.000129	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	5.29e-06	0.000129	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.27e-06	0.000128	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	5.26e-06	0.000128	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	5.17e-06	0.000126	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CA—ovarian cancer	5.14e-06	0.000125	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	5.11e-06	0.000124	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CB—ovarian cancer	5.1e-06	0.000124	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	5.09e-06	0.000124	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CAV1—ovarian cancer	5.08e-06	0.000124	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	5.07e-06	0.000123	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL2—ovarian cancer	5.06e-06	0.000123	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ERBB2—ovarian cancer	5.05e-06	0.000123	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	5.03e-06	0.000123	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CAV1—ovarian cancer	5.03e-06	0.000122	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CG—ovarian cancer	5.03e-06	0.000122	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CB—ovarian cancer	4.99e-06	0.000122	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	4.99e-06	0.000121	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MTOR—ovarian cancer	4.99e-06	0.000121	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CB—ovarian cancer	4.98e-06	0.000121	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CD—ovarian cancer	4.95e-06	0.00012	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	4.93e-06	0.00012	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CG—ovarian cancer	4.91e-06	0.000119	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	4.88e-06	0.000119	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.81e-06	0.000117	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CXCL8—ovarian cancer	4.79e-06	0.000117	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	4.79e-06	0.000117	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—HRAS—ovarian cancer	4.76e-06	0.000116	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	4.76e-06	0.000116	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CB—ovarian cancer	4.71e-06	0.000115	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	4.68e-06	0.000114	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	4.64e-06	0.000113	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	4.63e-06	0.000113	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	4.62e-06	0.000113	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CASP3—ovarian cancer	4.59e-06	0.000112	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	4.58e-06	0.000112	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL2—ovarian cancer	4.58e-06	0.000111	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL6—ovarian cancer	4.56e-06	0.000111	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.52e-06	0.00011	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—ovarian cancer	4.46e-06	0.000109	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	4.42e-06	0.000108	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	4.42e-06	0.000108	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTEN—ovarian cancer	4.4e-06	0.000107	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MMP9—ovarian cancer	4.33e-06	0.000105	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CB—ovarian cancer	4.31e-06	0.000105	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTEN—ovarian cancer	4.31e-06	0.000105	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.31e-06	0.000105	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTEN—ovarian cancer	4.31e-06	0.000105	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTEN—ovarian cancer	4.3e-06	0.000105	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CAV1—ovarian cancer	4.3e-06	0.000105	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	4.3e-06	0.000105	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	4.26e-06	0.000104	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	4.25e-06	0.000103	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	4.2e-06	0.000102	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.19e-06	0.000102	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TYMS—ovarian cancer	4.12e-06	0.0001	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.11e-06	0.0001	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTEN—ovarian cancer	4.07e-06	9.9e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	4.07e-06	9.9e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	4.06e-06	9.89e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	4.03e-06	9.81e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	3.96e-06	9.63e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	3.92e-06	9.53e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	3.89e-06	9.47e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	3.87e-06	9.42e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	3.87e-06	9.42e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—STAT3—ovarian cancer	3.85e-06	9.38e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	3.85e-06	9.37e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CA—ovarian cancer	3.85e-06	9.37e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NRAS—ovarian cancer	3.84e-06	9.36e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.76e-06	9.15e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTEN—ovarian cancer	3.73e-06	9.08e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	3.68e-06	8.96e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	3.65e-06	8.9e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MYC—ovarian cancer	3.58e-06	8.71e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	3.54e-06	8.62e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	3.51e-06	8.55e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	3.5e-06	8.53e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGFR—ovarian cancer	3.5e-06	8.52e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	3.44e-06	8.38e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	3.36e-06	8.17e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTEN—ovarian cancer	3.33e-06	8.1e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CAV1—ovarian cancer	3.32e-06	8.08e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KRAS—ovarian cancer	3.31e-06	8.05e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTEN—ovarian cancer	3.25e-06	7.91e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	3.25e-06	7.91e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—AKT1—ovarian cancer	3.15e-06	7.66e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CA—ovarian cancer	3.11e-06	7.56e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	3.11e-06	7.56e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTEN—ovarian cancer	3.06e-06	7.45e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CA—ovarian cancer	3.04e-06	7.41e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	3.04e-06	7.4e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CA—ovarian cancer	3.04e-06	7.39e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTEN—ovarian cancer	3.03e-06	7.39e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.02e-06	7.36e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	3e-06	7.3e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	2.97e-06	7.24e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—ovarian cancer	2.94e-06	7.16e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CA—ovarian cancer	2.87e-06	6.98e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HRAS—ovarian cancer	2.81e-06	6.84e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	2.74e-06	6.68e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL6—ovarian cancer	2.69e-06	6.55e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.66e-06	6.47e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CA—ovarian cancer	2.63e-06	6.4e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTEN—ovarian cancer	2.59e-06	6.31e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—AKT1—ovarian cancer	2.54e-06	6.18e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—AKT1—ovarian cancer	2.49e-06	6.05e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AKT1—ovarian cancer	2.48e-06	6.04e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—AKT1—ovarian cancer	2.48e-06	6.04e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.35e-06	5.71e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—AKT1—ovarian cancer	2.34e-06	5.7e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.32e-06	5.64e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.29e-06	5.58e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.16e-06	5.26e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—AKT1—ovarian cancer	2.15e-06	5.23e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.14e-06	5.21e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTEN—ovarian cancer	2e-06	4.87e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—AKT1—ovarian cancer	1.92e-06	4.67e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—AKT1—ovarian cancer	1.87e-06	4.56e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.83e-06	4.45e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—AKT1—ovarian cancer	1.76e-06	4.29e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—AKT1—ovarian cancer	1.75e-06	4.26e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—AKT1—ovarian cancer	1.49e-06	3.64e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.41e-06	3.44e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AKT1—ovarian cancer	1.15e-06	2.81e-05	CbGpPWpGaD
